Pfizer has put out a statement in response to the CMAJ varenicline article, asserting that the authors’ conclusions are misleading because they are based on a small number of cardiovascular events. Pfizer states that the study’s report of a 72% increase in adverse cardiovascular events among smokers using varenicline has been taken out of context. [...]
Pfizer has put out a statement in response to the CMAJ varenicline article, asserting that the authors’ conclusions are misleading because they are based on a small number of cardiovascular events. Pfizer states that the study’s report of a 72% increase in adverse cardiovascular events among smokers using varenicline has been taken out of context. The actual differences in the adverse cardiovascular event rates was less than a quarter of a percent–1.06 percent (52/4908) with varenicline vs. 0.82 percent (27/3308) with placebo.
Pfizer mentioned its commitment to safety and its collaboration with regulators like Health Canada and the USFDA–the latter with which Pfizer is working on a meta-analysis to help evaluate the cardiovascular safety of varenicline.
Pfizer encourages healthcare providers to contact Pfizer medical information at 1-800 463-6001 or consult the Champix/Chantix product monograph should they have any questions about the product.
Leave Your Response
You must be logged in to post a comment.